ixekizumab

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
05101520122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Psoriasis, a chronic, immune-mediated skin disease characterized by red, scaly plaques, affects approximately 0.3% of the… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2017
2017
BACKGROUND Safety of biologics is important when treating patients with psoriasis. OBJECTIVE We sought to determine the safety… (More)
Is this relevant?
2017
2017
BACKGROUND Scalp is a frequently affected and difficult-to-treat area in psoriasis patients. OBJECTIVE We assessed the efficacy… (More)
Is this relevant?
2016
2016
Interleukin (IL)-17A exists as a homodimer (A/A) or as a heterodimer (A/F) with IL-17F. IL-17A is expressed by a subset of T… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
OBJECTIVE To evaluate ixekizumab, an anti-interleukin 17A monoclonal antibody, for safety and effectiveness through 64 weeks in… (More)
Is this relevant?
2016
2016
IMPORTANCE Therapies that reduce psoriasis symptoms may improve work productivity. OBJECTIVE To assess the effect of ixekizumab… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
BACKGROUND Itch is a prevalent symptom of psoriasis that impacts quality of life. OBJECTIVE We sought to describe improvements… (More)
Is this relevant?
2015
2015
BACKGROUND Scalp and nail psoriasis have a major impact on quality of life and are traditionally resistant to therapy. Ixekizumab… (More)
Is this relevant?
2014
2014
BACKGROUND Patients with moderate to severe plaque psoriasis demonstrated positive responses to ixekizumab, an anti-interleukin… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table I
Is this relevant?
2014
2014
Ixekizumab (LY2439821), a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody that selectively binds and neutralizes… (More)
Is this relevant?